Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections

Journal of Clinical Pharmacology

Volumn 55, Issue 6, 2015, Pages 639-646

  Wicha, Sebastian G ^a   Haak, Thomas ^b   Zink, Karl ^b   Kees, Frieder ^c   Kloft, Charlotte ^a   Kees, Martin G ^a,d  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Diabetes Center Mergentheim   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

complicated skin and skin structure infections; fluoroquinolones; pharmacokinetic pharmacodynamic analysis; tissue concentrations

Indexed keywords

MOXIFLOXACIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CENTRAL VOLUME OF DISTRIBUTION; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC FOOT; DRUG CLEARANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; OBESITY; OPEN STUDY; PERIPHERAL VOLUME OF DISTRIBUTION; VOLUME OF DISTRIBUTION; AREA UNDER THE CURVE; DIABETES MELLITUS; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; MONTE CARLO METHOD; PATHOGENICITY; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DIABETES MELLITUS; DIABETIC FOOT; FEMALE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD;

EID: 84928883739     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.464     Document Type: Article

References (26)

1. Lipsky BA, Berendt AR, Cornia PB, et al. Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012; 54 (12): e132-e173.
2. Andersson MI, MacGowan AP,. Development of the quinolones. J Antimicrob Chemother. 2003; 51 (suppl 1): 1-11.
3. Summary of Product Characteristics-Avelox 400 mg/250 ml solution for infusion. http://www.medicines.org.uk/emc/medicine/22827/SPC
4. Beckmann J, Kees F, Schaumburger J, et al. Tissue concentrations of vancomycin and Moxifloxacin in periprosthetic infection in rats. Acta Orthop. 2007; 78 (6): 766-773.
5. Kees MG, Weber S, Kees F, Horbach T,. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother. 2011; 66 (10): 2330-2335.
6. Green B, Duffull SB,. What is the best size descriptor to use for pharmacokinetic studies in the obese. Br J Clin Pharmacol. 2004; 58 (2): 119-133.
7. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16 (1): 31-41.
8. Gastonguay MR,. A full estimation model approach for covariate effects: inference based on clinical importance estimation precision. AAPS J. 2004; 6 (S1): W4354.
9. Wispelwey B,. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Infect Dis. 2005; 41 (suppl 2): S127-S135.
10. Anderson BJ, Holford NHG,. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008; 48 (1): 303-332.
11. Mould DR, Holford NHG, Schellens JHM, et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther. 2002; 71 (5): 334-348.
12. Savic RM, Karlsson MO,. Importance of shrinkage in empirical bayes estimates for diagnostics: problems solutions. AAPS J. 2009; 11 (3): 558-569.
13. Stass H, Kubitza D,. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother. 1999; 43 (90002): 83-90.
14. Stass H, Kubitza D, Halabi A, Delesen H,. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol. 2002; 53 (3): 232-237.
15. Majcher-Peszynska J, Sass M, Schipper S, et al. Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. Eur J Clin Pharmacol. 2011; 67 (2): 135-142.
16. Gyssens IC, Dryden M, Kujath P, et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother. 2011; 66 (11): 2632-2642.
17. Schaper NC, Dryden M, Kujath P, et al. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection. 2013; 41 (1): 175-186.
18. Ambrose PG, Bhavnani SM, Owens RC Jr,. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am. 2003; 17 (3): 529-543.
19. Mouton JW, Brown DFJ, Apfalter P, et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect. 2012; 18 (3): E37-E45.
20. Moxifloxacin-Rationale for the EUCAST clinical beakpoints, version 2.3. 2007. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Rationale-documents/Moxifloxacin-rationale-2.3.pdf
21. Landersdorfer CB, Kinzig M, Hennig FF, et al. Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation. Antimicrob Agents Chemother. 2009; 53 (5): 2074-2081.
22. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O,. Tissue concentrations: do we ever learn. J Antimicrob Chemother. 2008; 61 (2): 235-237.
23. Brunner M, Derendorf H, Müller M,. Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr Opin Pharmacol. 2005; 5 (5): 495-499.
24. Müller M, Brunner M, Hollenstein U, et al. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob Agents Chemother. 1999; 43 (8): 2056-2058.
25. Joukhadar C, Stass H, Müller-Zellenberg U, et al. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother. 2003; 47 (10): 3099-3103.
26. Bellmann R, Kuchling G, Dehghanyar P, et al. Tissue pharmacokinetics of levofloxacin in human soft tissue infections. Br J Clin Pharmacol. 2004; 57 (5): 563-568.